Outpatient parenteral antimicrobial therapy practices among adult infectious disease physicians

Infection Control and Hospital Epidemiology

Volumn 35, Issue 7, 2014, Pages 839-844

  Lane, Michael A ^a   Marschall, Jonas ^a   Beekmann, Susan E ^b   Polgreen, Philip M ^b   Banerjee, Ritu ^c   Hersh, Adam L ^d   Babcock, Hilary M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMPHOTERICIN; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; DAPTOMYCIN; NAFCILLIN; OXACILLIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; BLOOD CLOTTING; BLOODSTREAM INFECTION; CLOSTRIDIUM DIFFICILE INFECTION; CYTOPENIA; DEEP VEIN THROMBOSIS; HEALTH SURVEY; HOSPITAL PHYSICIAN; HUMAN; INFECTION; LABORATORY TEST; MEDICAL PRACTICE; NEPHROTOXICITY; NONHUMAN; OCCLUSION; OUTPATIENT CARE; PUBLIC HEALTH SERVICE; RASH; AMBULATORY CARE; ANTIBIOTIC PROPHYLAXIS; CROSS INFECTION; HEALTH CARE SURVEY; INFECTION CONTROL; INFECTION CONTROL PRACTITIONER; NORTH AMERICA; PROCEDURES;

AMBULATORY CARE; ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; CROSS INFECTION; HEALTH CARE SURVEYS; HUMANS; INFECTION CONTROL; INFECTION CONTROL PRACTITIONERS; NORTH AMERICA;

EID: 84902989975     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/676859     Document Type: Article

References (27)

1. Leder K, Turnidge JD, Grayson ML. Home-based treatment of cellulitis with twice-daily cefazolin. Med J Aust 1998;169(10): 519-522.
2. Nathwani D. The management of skin and soft tissue infections: outpatient parenteral antibiotic therapy in the United Kingdom. Chemotherapy 2001;47(suppl 1):17-23.
3. Eron LJ, Goldenberg RI, Poretz DM. Combined ceftriaxone and surgical therapy for osteomyelitis in hospital and outpatient settings. Am J Surg 1984;148(4A):1-4.
4. Tice AD. Outpatient parenteral antimicrobial therapy for osteomyelitis. Infect Dis Clin North Am 1998;12(4):903-919.
5. Esposito S, Noviello S, Leone S, et al. Outpatient parenteral antibiotic therapy (OPAT) in different countries: a comparison. Int J Antimicrob Agents 2004;24(5):473-478.
6. Duggal A, Barsoum W, Schmitt SK. Patients with prosthetic joint infection on IV antibiotics are at high risk for readmission. Clin Orthop Relat Res 2009;467(7):1727-1731.
7. Rehm SJ. Outpatient intravenous antibiotic therapy for endocarditis. Infect Dis Clin North Am 1998;12(4):879-901.
8. Chary A, Tice AD, Martinelli LP, Liedtke LA, Plantenga MS, Strausbaugh LJ. Experience of infectious diseases consultants with outpatient parenteral antimicrobial therapy: results of an emerging infections network survey. Clin Infect Dis 2006;43(10): 1290-1295.
9. Montalto M. Patients' and carers' satisfaction with hospital-inthe- home care. Int J Qual Health Care 1996;8(3):243-251.
10. Hindes R, Winkler C, Kane P, Kunkel M. Outpatient intravenous antibiotic therapy in medicare patients: cost-savings analysis. Infect Dis Clin Pract 1995;4(3):211-217.
11. Poretz DM, Woolard D, Eron LJ, Goldenberg RI, Rising J, Sparks S. Outpatient use of ceftriaxone: a cost-benefit analysis. Am J Med 1984;77(4C):77-83.
12. Williams DN, Bosch D, Boots J, Schneider J. Safety, efficacy, and cost savings in an outpatient intravenous antibiotic program. Clin Ther 1993;15(1):169-179; discussion 168.
13. Tice AD, Rehm SJ, Dalovisio JR, et al. Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis 2004;38(12):1651-1672.
14. Executive Committee of the Infectious Diseases Society of America Emerging Infections Network. The emerging infections network: a new venture for the Infectious Diseases Society of America. Clin Infect Dis 1997;25(1):34-36.
15. US Department of Commerce. Census regions and divisions of the United States. http://www.census.gov/geo/maps-data/maps/pdfs/reference/us_regdiv.pdf. Accessed May 1, 2014.
16. Chapman AL, Seaton RA, Cooper MA, et al. Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement. J Antimicrob Chemother 2012;67(5):1053-1062.
17. Sharma R, Loomis W, Brown RB. Impact of mandatory inpatient infectious disease consultation on outpatient parenteral antibiotic therapy. Am J Med Sci 2005;330(2):60-64.
18. Shrestha NK, Bhaskaran A, Scalera NM, Schmitt SK, Rehm SJ, Gordon SM. Contribution of infectious disease consultation toward the care of inpatients being considered for communitybased parenteral anti-infective therapy. J Hosp Med 2012;7(5): 365-369.
19. Tice AD. Outpatient parenteral antibiotic therapy (OPAT) in the United States: delivery models and indications for use. Can J Infect Dis 2000;11(suppl A):17A-21A.
20. Berman SJ, Johnson EW. Out-patient parenteral antibiotic therapy (OPAT): clinical outcomes and adverse events. Hawaii Med J 2001;60(2):31-33.
21. Tice A. The use of outpatient parenteral antimicrobial therapy in the management of osteomyelitis: data from the Outpatient Parenteral Antimicrobial Therapy Outcomes Registries. Chemotherapy 2001;47(suppl 1):5-16.
22. Tice AD, Hoaglund PA, Nolet B, McKinnon PS, Mozaffari E. Cost perspectives for outpatient intravenous antimicrobial therapy. Pharmacotherapy 2002;22(2 pt 2):63S-70S.
23. Rehm SJ, Longworth DL. Rates of adverse events associated with community-based parenteral anti-infective therapy. J Clin Outcomes Manage 2000;7(10):23-28.
24. Cervera C, del Rio A, Garcia L, et al. Efficacy and safety of outpatient parenteral antibiotic therapy for infective endocarditis: a ten-year prospective study. Enferm Infecc Microbiol Clin 2011;29(8):587-592.
25. Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations: a literature review. Eur J Clin Pharmacol 2012;68(9):2143-2155.
26. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66(1):82-98.
27. van Hal SJ, Paterson DL, Lodise TP. Systematic review and metaanalysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agent Chemother 2013;57(2):734-744.